Navigation Links
Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
Date:2/9/2009

---- ---- Total stockholders' equity 1,436.0 1,441.7 ------- ------- Total liabilities and stockholders' equity $3,572.8 $3,594.3 ======== ======== BECKMAN COULTER, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (unaudited) Year Ended December 31, ----------------------- 2008 2007 ---- ---- Cash flows from operating activities Net earnings $194.0 $211.3 Less: Earnings from discontinued operations, net of tax - 1.6 --- --- Earnings from continuing operations 194.0 209.7 Adjustments to reconcile net earnings to net cash provided by operating activities Depreciation and amortization 255.9 203.0 Provision for doubtful accounts receivable 6.8 4.7 Share-based compensation expense 29.6 24.5 Gain on sales of building and land (5.1) (26.8) Environmental remediation obligation 18.4 - U.S. pension trust contributions (8.2) (9.3) In-process research and development - 35
'/>"/>
SOURCE Beckman Coulter - IR
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Beckman Coulter to Present at the Bear Stearns Healthcare Conference
2. Beckman Coulter to Present at the UBS Global Life Sciences Conference
3. Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens
4. Beckman Coulter Declares Quarterly Dividend
5. Beckman Coulter Announces Third Quarter 2007 Results
6. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
7. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
8. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
9. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  Today, Americord ... the U.S., announced Andrew Horne , a partner at ... Advisory Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... appointment to Americord,s Advisory Board," says Martin Smithmyer , ... experience in his legal career that will assist Americord,s growth ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... The maximum ... of Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). On June ... the last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... its Phase 1/2 clinical trial of RCT-01, being ... tendinosis, has been enrolled and their tissue biopsy ... RCT-01 is comprised of non-bulbar dermal sheath (NBDS) ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Medarex, Inc.,(Nasdaq: MEDX ) announced today that it ... Emerging Growth Conference in New York City on Tuesday,September ... will be,webcast live and will be available for replay ... the Medarex website via the Internet at, http://www.medarex.com ...
... Leading scientists,from around the world will meet in ... producing life-saving vaccines and,antibodies. More than 125 scientists ... for New Vaccines II: Focus on Respiratory Virus,Diseases" ... The international,scientific workshop is being organized by the ...
... (Amex: PTN ) stated today that the ... Technologies, Inc. (Amex: CTT ),relating to a ... was,false and misleading. The press release issued ... with Palatin Technologies." However, the,Notice of Termination sent ...
Cached Biology Technology:International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development 2Palatin Technologies Refutes Competitive Technologies Contention of Material Breach 2
(Date:6/15/2015)... Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces that its leading payment ... media at Digital Experience! @ NYC June 18th. ... the latest innovation in technology to over 300 of the ... at the Metropolitan Pavilion in New York City ...
(Date:6/10/2015)... June 10, 2015 According ... Market by Technology (Ultrasound, TOF, Structured Light, Stereo ... Entertainment, Automotive) and by Geography - Trends & ... the market is expected to reach $3,319.71 Million ... between 2015 and 2020. Browse 71 ...
(Date:6/8/2015)... Inc. (NASDAQ: TROV ), a developer of cell-free molecular ... Monitoring SM platform will be presented at the ... San Diego, CA on June 11-12 , and ... and Cancer Therapy in Salt Lake City, ... continue to advance our clinical programs and present data to ...
Breaking Biology News(10 mins):Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 33D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... very good at what they do. But they don,t ... work in oily or dangerous environments, or in any kind ... of the fastest and most maneuverable creatures on the planet, ... to their streamlined bodies and a finely tuned muscular/sensory/control system. ...
... Rochelle, NY, September 19, 2012 Many biotech observers ... be based on the field of personalized medicine, ... ( GEN ) ( http://genengnews.com ). Although drug ... of biosamples, demand is exceeding supply, fueling the ...
... researchers at Michigan State University has documented the step-by-step process ... in the current issue of Nature , are revealed ... coli bacteria figured out how to supplement a traditional ... "It,s pretty nifty to see a new biological function evolve," ...
Cached Biology News:Robotic tuna is built by Homeland Security 2Evolution is as complicated as 1-2-3 2
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 19 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
... array sample elements. , ,Includes: , DiscoverLight ... BSA in PBS (10X): 50 ml , ... , BupH Phosphate Buffered Saline: 8 packs ... ml ampules , SuperSignal West Pico Luminol Enhancer: 2 ...
Biology Products: